At a glance
ClinicalIndex Comparison RecordN/ACompleted· 528 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Reliability of Effect of Rimegepant for the Acute Treatment of Migraine Across Multiple Attacks
In Brief
An observational study for Migraine Disorders. Completed, enrolled 528 participants across 1 site.
Detailed Summary
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartJan 2024
Primary CompletionJan 2024
First PostedMay 2024
TodayJul 2026
First PostedMay 14, 2024
Enrollment StartJan 2, 2024
Primary CompletionJan 3, 2024
TodayJul 2, 2026
Enrollment to primary: 1 daysPosted 2.1 years ago